Key Takeaways:
-
The $90m raise was led by RA Capital Management and included both old and new investors.
-
SpyGlass designs intraocular lenses secured by drug-eluting pads to deliver controlled drug release.
-
Work is underway for an IND filing in glaucoma with a Phase I/II trial planned for later this year.
SpyGlass Pharma is using its proprietary intraocular drug-delivery system to develop more convenient treatment options for chronic eye diseases with the help of a
The round was led by RA Capital Management alongside historical investors New Enterprise Associates and Vensana Capital, and also included new investors Samsara BioCapital and Vertex Ventures
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?